Skip to main content

Advertisement

Figure 3 | Alzheimer's Research & Therapy

Figure 3

From: First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model

Figure 3

Active vaccination reduced the number of transgenic rats developing extensive neurofibrillary pathology. Immunostaining with AT8, pT212 and pS214 shows low numbers of neurofibrillary tangles in the brainstem of treated transgenic rats (A), (D) and (G) compared with untreated transgenic rats (B), (E) and (H). Immunisation lowered the number of transgenic rats with extensive neurofibrillary degeneration by 55% (C) and (F) or by 77% (I).

Back to article page